Generic filters
Filter by content type
Taxonomy terms

AURA – Aura Biosciences Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 30.75

Low: 26

High: 38

Total Analysts: 4

Company Profile

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing virus-like drug conjugates (VDCs), a novel class of therapies for the treatment of multiple oncology indications. The Company’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 consists of human papilloma virus (HPV)-derived VLP conjugated to hundreds of infrared laser-activated molecules. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is in development for ocular cancers, with an ongoing Phase II dose escalation clinical trial evaluating first-line treatment of choroidal melanoma. It seeks to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan